Gregory Y.H. Lip-rekin lankidetzan egindako argitalpenak (15)

2024

  1. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

    Nature Reviews Cardiology, Vol. 21, Núm. 8, pp. 574-592

2023

  1. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

    Thrombosis and haemostasis, Vol. 123, Núm. 7, pp. 723-733

2022

  1. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

    The BMJ, Vol. 376

  2. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes

    European Journal of Internal Medicine, Vol. 103, pp. 76-83

  3. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

    JAMA Cardiology, Vol. 7, Núm. 7, pp. 747-759

2021

  1. Association between preexisting versus newly identified atrial fibrillation and outcomes of patients with acute pulmonary embolism

    Journal of the American Heart Association, Vol. 10, Núm. 17

  2. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 16, pp. 1620-1630

  3. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 1, pp. 131-141

  4. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 16, pp. 1635-1654

  5. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 77, Núm. 15, pp. 1903-1921

  6. SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia

    Thrombosis and Haemostasis, Vol. 121, Núm. 8, pp. 982-991

2020

  1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 75, Núm. 23, pp. 2950-2973

  2. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies

    Thrombosis Research, Vol. 196, pp. 382-394

  3. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

    Thrombosis and Haemostasis, Vol. 120, Núm. 7, pp. 1004-1024

2019

  1. Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry

    Seminars in Thrombosis and Hemostasis, Vol. 45, Núm. 8, pp. 793-801